Nontuberculous Mycobacterial Pulmonary Disease: Patients, Principles, and Prospects
Minh-Vu H Nguyen, Michelle Haas, Shannon Kasperbauer, Vinicius Calado Nogueira de Moura, Jared J Eddy, John D. Mitchell, Reeti Khare, David E. Griffith, Edward D. Chan, Charles L. Daley
Abstract
Nontuberculous mycobacterial pulmonary disease (NTM-PD) is increasing in incidence globally and challenging to manage. The 2020 multisociety treatment guideline and the 2022 consensus recommendations provide comprehensive evidence-based guides to manage pulmonary diseases caused by the most common NTM. However, with >190 different NTM species that may require different multidrug regimens for treatment, the breadth and complexity of NTM-PD remain daunting for both patients and clinicians. In this narrative review, we aim to distill this broad, complex field into principles applicable to most NTM species and highlight important nuances, specifically elaborating on the presentation, diagnosis, principles of patient-centered care, principles of pathogen-directed therapy, and prospects of NTM-PD.